{"organizations": [], "uuid": "0536b1742c0ce6417d3b699a0d13d02fdc05844f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-amarins-says-100-pct-mark-reached/brief-amarins-says-100-pct-mark-reached-on-reduce-it-cardiovascular-outcomes-study-for-estimated-onset-of-target-primary-mace-idUSFWN1RH017", "country": "US", "domain_rank": 408, "title": "BRIEF-Amarin's says 100 pct Mark reached on REDUCE-IT Cardiovascular Outcomes Study for Estimated Onset of Target Primary MACE", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-04T12:06:00.000+03:00", "replies_count": 0, "uuid": "0536b1742c0ce6417d3b699a0d13d02fdc05844f"}, "author": "", "url": "https://www.reuters.com/article/brief-amarins-says-100-pct-mark-reached/brief-amarins-says-100-pct-mark-reached-on-reduce-it-cardiovascular-outcomes-study-for-estimated-onset-of-target-primary-mace-idUSFWN1RH017", "ord_in_thread": 0, "title": "BRIEF-Amarin's says 100 pct Mark reached on REDUCE-IT Cardiovascular Outcomes Study for Estimated Onset of Target Primary MACE", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "estimated onset of target primary mace reuters staff", "sentiment": "none"}, {"name": "amarin corporation plc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 4 (Reuters) - Amarin Corporation PLC:\n* IT CARDIOVASCULAR OUTCOMES STUDY REACHES 100% MARK FOR ESTIMATED ONSET OF TARGET PRIMARY MAJOR ADVERSE CARDIOVASCULAR EVENTS\n* MAINTAINS ITS GUIDANCE TO REPORT TOP-LINE RESULTS FROM STUDY BEFORE END OF Q3 2018. Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-04-04T12:06:00.000+03:00", "crawled": "2018-04-04T12:55:25.017+03:00", "highlightTitle": ""}